CAMBRIDGE, Mass., June 20, 2025 -- Wave Life Sciences Ltd. (Nasdaq: WVE) has announced the presentation of preclinical data supporting their investigational drug WVE-007 at the American Diabetes Association's 85th Annual Scientific Sessions in Chicago. WVE-007 is a GalNAc-siRNA designed to silence INHBE mRNA, targeting obesity with evidence from human genetics. The preclinical data demonstrated the drug's capacity to reduce INHBE mRNA and Activin E protein, facilitate weight loss primarily through fat mass reduction, and diminish pro-inflammatory macrophage recruitment in a diet-induced obese mouse model. These findings were highlighted in an oral presentation at the event, which takes place from June 20 to 23, 2025. Wave Life Sciences is currently evaluating WVE-007 in their ongoing INLIGHT clinical trial, with the first clinical data expected in the latter half of this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.